Is Aura Biosciences Stock a Good Investment?
Aura Biosciences Investment Advice | AURA |
- Examine Aura Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Aura Biosciences' leadership team and their track record. Good management can help Aura Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Aura Biosciences' business and its evolving consumer preferences.
- Compare Aura Biosciences' performance and market position to its competitors. Analyze how Aura Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Aura Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Aura Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Aura Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Aura Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Aura Biosciences Stock
Researching Aura Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 78.0% of the company shares are held by institutions such as insurance companies. The book value of Aura Biosciences was presently reported as 3.51. The company recorded a loss per share of 1.73. Aura Biosciences had not issued any dividends in recent years.
To determine if Aura Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aura Biosciences' research are outlined below:
| Aura Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (76.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aura Biosciences currently holds about 122.13 M in cash with (63.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.17. | |
| Aura Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
Aura Biosciences Quarterly Cash And Short Term Investments |
|
Aura Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aura Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aura Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Aura Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Aura Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-11 | 2023-03-31 | -0.54 | -0.46 | 0.08 | 14 | ||
2024-05-09 | 2024-03-31 | -0.49 | -0.4 | 0.09 | 18 | ||
2024-03-12 | 2023-12-31 | -0.41 | -0.56 | -0.15 | 36 | ||
2021-11-24 | 2021-09-30 | -0.45 | -0.25 | 0.2 | 44 | ||
2022-03-23 | 2021-12-31 | -0.39 | -2.51 | -2.12 | 543 |
Know Aura Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aura Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aura Biosciences backward and forwards among themselves. Aura Biosciences' institutional investor refers to the entity that pools money to purchase Aura Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 728 K | Regency Capital Management Inc.\de | 2024-09-30 | 667.3 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 573.6 K | Decheng Capital Llc | 2024-06-30 | 515.6 K | Easterly Investment Partners. | 2024-09-30 | 413.6 K | Northern Trust Corp | 2024-09-30 | 364.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 292.8 K | Ensign Peak Advisors Inc | 2024-09-30 | 272.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 165.7 K | Matrix Capital Management Company, Llc | 2024-06-30 | 6.9 M | Eventide Asset Management, Llc | 2024-09-30 | 5.8 M |
Aura Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 465.05 M.Market Cap |
|
Aura Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.34) | (0.32) |
Determining Aura Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Aura Biosciences is a good buy. For example, gross profit margin measures Aura Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aura Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Aura Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aura Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aura Biosciences' management manipulating its earnings.
Evaluate Aura Biosciences' management efficiency
Aura Biosciences has return on total asset (ROA) of (0.3022) % which means that it has lost $0.3022 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5099) %, meaning that it created substantial loss on money invested by shareholders. Aura Biosciences' management efficiency ratios could be used to measure how well Aura Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, Aura Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.3 M, whereas Total Assets are forecasted to decline to about 153.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.70 | 5.99 | |
| Tangible Book Value Per Share | 5.70 | 5.99 | |
| Enterprise Value Over EBITDA | (3.94) | (4.13) | |
| Price Book Value Ratio | 1.55 | 1.63 | |
| Enterprise Value Multiple | (3.94) | (4.13) | |
| Price Fair Value | 1.55 | 1.63 | |
| Enterprise Value | 400.1 M | 426.5 M |
The strategic initiatives led by Aura Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.332 |
Basic technical analysis of Aura Stock
As of the 30th of November, Aura Biosciences shows the Mean Deviation of 2.65, risk adjusted performance of 0.0724, and Downside Deviation of 2.99. Aura Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Aura Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aura Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aura Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aura Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aura Biosciences' Outstanding Corporate Bonds
Aura Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aura Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aura bonds can be classified according to their maturity, which is the date when Aura Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Aura Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Aura Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0724 | |||
| Market Risk Adjusted Performance | 1.31 | |||
| Mean Deviation | 2.65 | |||
| Semi Deviation | 2.67 | |||
| Downside Deviation | 2.99 | |||
| Coefficient Of Variation | 1186.99 | |||
| Standard Deviation | 3.79 | |||
| Variance | 14.33 | |||
| Information Ratio | 0.0479 | |||
| Jensen Alpha | 0.2785 | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | 0.0607 | |||
| Treynor Ratio | 1.3 | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (4.95) | |||
| Potential Upside | 7.71 | |||
| Downside Variance | 8.92 | |||
| Semi Variance | 7.15 | |||
| Expected Short fall | (2.95) | |||
| Skewness | 1.27 | |||
| Kurtosis | 2.89 |
| Risk Adjusted Performance | 0.0724 | |||
| Market Risk Adjusted Performance | 1.31 | |||
| Mean Deviation | 2.65 | |||
| Semi Deviation | 2.67 | |||
| Downside Deviation | 2.99 | |||
| Coefficient Of Variation | 1186.99 | |||
| Standard Deviation | 3.79 | |||
| Variance | 14.33 | |||
| Information Ratio | 0.0479 | |||
| Jensen Alpha | 0.2785 | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | 0.0607 | |||
| Treynor Ratio | 1.3 | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (4.95) | |||
| Potential Upside | 7.71 | |||
| Downside Variance | 8.92 | |||
| Semi Variance | 7.15 | |||
| Expected Short fall | (2.95) | |||
| Skewness | 1.27 | |||
| Kurtosis | 2.89 |
Consider Aura Biosciences' intraday indicators
Aura Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aura Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Aura Biosciences Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 29th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Aura Stock media impact
Far too much social signal, news, headlines, and media speculation about Aura Biosciences that are available to investors today. That information is available publicly through Aura media outlets and privately through word of mouth or via Aura internal channels. However, regardless of the origin, that massive amount of Aura data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aura Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aura Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aura Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aura Biosciences alpha.
Aura Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Aura Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aura Biosciences Corporate Management
| Richard Mountfield | Senior Quality | Profile | |
| Patrick Nealon | Senior Operations | Profile | |
| CPE MBA | Chief RD | Profile | |
| Jill MD | Chief Development | Profile | |
| Amy Elazzouzi | Interim Officer | Profile | |
| Paulo Carvalho | VP Operations | Profile | |
| Bruce MD | Senior Oncology | Profile |
Already Invested in Aura Biosciences?
The danger of trading Aura Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aura Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aura Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aura Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Return On Assets (0.30) | Return On Equity (0.51) |
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Aura Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.